DIFFUSE LARGE B CELL LYMPHOMA

This early-stage trial is testing whether adding an experimental drug called E7777 before standard CAR-T cell therapy can improve results for adults with aggressive B-cell lymphomas that have returned or not responded to prior treatments. The drug aims to help the CAR-T cells wor…

This study is testing if a blood test can quickly detect tiny amounts of leftover cancer after patients receive CAR-T cell therapy for a type of lymphoma that has come back or not responded to other treatments. The goal is to see if getting these test results within three weeks c…

This trial is testing whether a new injectable drug called epcoritamab works better than standard chemotherapy for people with an aggressive type of lymphoma that has come back or stopped responding to prior treatment. About 484 participants will be randomly assigned to receive e…

This trial is testing if a new drug called epcoritamab works better than standard chemotherapy for people with an aggressive type of lymphoma that has come back or stopped responding to prior treatments. Participants will be randomly assigned to receive either the new drug as an …

This large, late-stage study is testing whether adding two newer drugs (tafasitamab and lenalidomide) to the standard R-CHOP chemotherapy helps people with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) live longer without their cancer getting worse. It will com…

This trial is testing a more personalized approach to treating an aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL). It aims to see if adjusting the standard treatment based on early results from PET scans and a special blood test (ctDNA) can improve outcomes. …

This study is testing a new way to give standard chemotherapy (R-CHOP) to older adults with an aggressive type of lymphoma called DLBCL. The goal is to split the doses over two weeks instead of giving them all at once, which researchers hope will be easier for older patients to t…

This study tests a personalized treatment called CAR-T cell therapy for children and young adults whose B-cell blood cancers have returned or resisted standard treatments. Doctors collect a patient's own immune cells, modify them in a lab to better target cancer cells, and then i…

This study compares two drug combinations for patients whose aggressive lymphoma has returned or stopped responding to previous treatments. Researchers are testing whether adding a new drug called glofitamab to standard chemotherapy works better and is safer than the current stan…

This early-stage study is testing if adding a new drug called parsaclisib to a standard chemotherapy regimen (R-CHOP) is safe and more effective for patients with newly diagnosed, high-risk diffuse large B-cell lymphoma. The main goals are to find the safest dose of the new combi…

This study is testing whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (called DA-REPOCH) works better for treating aggressive B-cell non-Hodgkin's lymphoma. The goal is to see if this combination helps patients live longer without their cancer g…

This large, late-stage study is testing whether adding a newer targeted drug called acalabrutinib to a standard chemotherapy regimen (R-CHOP) works better for people under 75 with a specific, harder-to-treat type of aggressive lymphoma. The main goal is to see if the new combinat…

This early-stage study is testing the safety of a new cancer drug called PF-08046032, both by itself and combined with another drug called sasanlimab. It involves a small group of adults with advanced or spreading cancers, including certain lymphomas and solid tumors like lung ca…

This study follows 1000 Chinese adults with diffuse large B-cell lymphoma (DLBCL) to see how well the drug polatuzumab works in real-world clinical practice. It aims to measure how long patients live without their cancer getting worse and to monitor side effects. The study includ…

This early-stage study is testing a new, experimental antibody drug called GNC-038 in adults whose diffuse large B-cell lymphoma (DLBCL) has come back or hasn't responded to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Resea…

This study is testing a new drug called MT-2111 for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has returned or hasn't responded to at least two prior treatments. The first part checks the drug's safety and the best dose, while…

This study is testing whether giving vitamin D supplements to cancer patients who have low vitamin D levels can help improve their survival and delay the need for other treatments. It focuses on people newly diagnosed with certain aggressive lymphomas or a slow-growing type of le…

This study is testing an experimental drug called iopofosine I 131 in people with various advanced B-cell blood cancers that have come back or stopped responding to standard treatments. The drug is designed to deliver radiation directly to cancer cells. The main goal is to see if…

This study is testing a new four-drug combination (rituximab, lenalidomide, acalabrutinib, tafasitamab) given before and alongside standard chemotherapy for adults newly diagnosed with a hard-to-treat type of aggressive lymphoma (non-germinal center DLBCL). The goal is to see if …

This study is testing a new combination of cancer drugs for people with an aggressive type of lymphoma (DLBCL) that has returned or not responded to the first treatment. The goal is to see if adding a newer targeted drug (polatuzumab vedotin) to a standard chemotherapy mix can he…

This study is testing the safety and effectiveness of a two-drug combination (tafasitamab plus lenalidomide) for adults with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It is for people whose cancer has returned or did not respond to 1 to 3 pr…

This trial is testing the safety and early effectiveness of a new drug called epcoritamab, given alone or combined with standard treatments, for people with B-cell non-Hodgkin lymphoma. It includes over 500 participants with different types and stages of the disease, including ne…

This study is testing several combinations of a drug called tafasitamab, along with other medications, for Japanese adults with Non-Hodgkin Lymphoma. The main goals are to find safe doses and see how well these combinations work to control the cancer. It includes people whose can…

This study collects a person's own white blood cells to potentially make a future cancer treatment called CAR-T cell therapy. It is for children and adults (ages 3-65) with certain types of leukemia or lymphoma that have not been cured by standard treatments. The collected cells …

This study is testing if adding a new drug called selinexor to the standard chemotherapy regimen (RCHOP) is safe and more effective for treating B-cell non-Hodgkin's lymphoma. It will first find the safest dose of the combination, then see how well it works for newly diagnosed pa…

This study is testing if adding a drug called vorinostat to standard medications can better prevent graft-versus-host disease (GVHD) in children and young adults getting a bone marrow transplant for blood cancers. GVHD is a serious complication where the donor's immune cells atta…

This study is testing an experimental drug called DZD8586 for adults with an aggressive type of lymphoma (DLBCL) that has come back or stopped responding to previous treatments. The main goal is to see if the drug can shrink tumors and control the disease. Researchers will also c…

This study is testing a new type of personalized immune cell therapy called rapcabtagene autoleucel (a CAR-T cell therapy) for adults with several aggressive or returning blood cancers. The main goals are to find a safe and effective dose and to see if the therapy can shrink or e…

This study is testing a new type of personalized cell therapy called MB-CART2019.1 for adults with an aggressive form of lymphoma that has come back or not responded to standard chemotherapy. The therapy involves modifying a patient's own immune cells to better find and attack ca…

This study is testing a new oral medication called nemtabrutinib for people with advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for a…

This trial is testing a drug called epcoritamab, alone or combined with standard treatments, for Japanese adults with B-cell lymphomas that have returned or not responded to prior therapy. The first part finds the safest and most effective dose. The second part treats more people…

This study is testing whether combining two existing cancer drugs, copanlisib and venetoclax, can help control an aggressive type of lymphoma called DLBCL that has returned or stopped responding to other treatments. The first part of the study aims to find a safe dose, and the se…

This study is testing if adding a pill called venetoclax to standard chemotherapy works better than chemotherapy alone for people with aggressive types of B-cell lymphoma. The goal is to better control the cancer and keep it from coming back. About 363 adults with specific, hard-…

This large, late-stage trial is testing whether adding a newer targeted drug (polatuzumab vedotin) to a standard chemotherapy regimen works better for people newly diagnosed with an aggressive type of blood cancer called diffuse large B-cell lymphoma. It will compare the new comb…

This study is testing a new, modified dosing schedule for a drug combination (tafasitamab plus lenalidomide) in patients whose diffuse large B-cell lymphoma has come back or hasn't responded to prior treatments. The main goals are to check the safety of this new schedule and see …

This study is for people with an aggressive type of blood cancer called DLBCL that has returned or not responded to at least two prior treatments. It tests whether adding a drug called brentuximab vedotin to the standard two-drug therapy (lenalidomide and rituximab) helps patient…

This study is testing the safety and effectiveness of a new three-medicine combination for adults with an aggressive type of lymphoma (DLBCL) that has come back or stopped responding to prior treatments. The trial is for people who are not eligible for or do not want a stem cell …

This early-phase trial is testing whether adding an experimental drug called zanubrutinib to standard chemotherapy is safe and tolerable for adults newly diagnosed with an aggressive type of blood cancer called diffuse large B-cell lymphoma. The main goal is to find the best dose…

This study is testing if a lower dose and smaller area of radiation treatment can work as well as the standard dose for patients with a type of blood cancer called diffuse large B-cell lymphoma. It is for people who have already finished chemotherapy and have a negative PET scan.…

This is an early-stage study testing a new antibody drug called IMT-009 in people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand the side effects, and see if the drug helps shrink tum…

This is an early-stage study to find the safest dose of two cancer drugs, copanlisib and nivolumab, when given together. It is for adults with aggressive blood cancers that have transformed from slower-growing types, like Richter's syndrome. The main goal is to see how well patie…

This study is testing two treatment approaches for elderly patients newly diagnosed with an aggressive type of lymphoma who cannot tolerate standard chemotherapy. Participants will receive either a single antibody drug or that same drug combined with another medication. The goal …

This study is testing whether adding a new targeted drug called polatuzumab vedotin to standard chemotherapy works better for people with aggressive types of B-cell lymphoma. The trial aims to see if this combination helps more patients achieve complete remission and controls the…

This study aims to improve the experience for lymphoma survivors by training their doctors in better communication skills. It involves 314 patients with Hodgkin's or Diffuse Large B-cell Lymphoma who have finished curative treatment and are in remission. The research will measure…

This study is testing a new nanochip technology that analyzes blood samples to monitor how well treatment is working and to try to detect if cancer returns earlier in patients with diffuse large B-cell lymphoma. Researchers will collect blood from 73 patients at diagnosis, during…